Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.
Herrera A, Fredholm S, Cheng A, Mimitou EP, Seffens A, Bar-Natan M, Sun A, Latkowski JA, Willerslew-Olsen A, Buus TB, Gluud M, Krejsgaard T, Torres-Rusillo S, Bonefeld CM, Woetmann A, Geisler C, Geskin LJ, Ouyang Z, Smibert P, Ødum N, Koralov SB. Herrera A, et al. J Invest Dermatol. 2020 Mar;140(3):713-716. doi: 10.1016/j.jid.2019.07.714. Epub 2019 Aug 26. J Invest Dermatol. 2020. PMID: 31465740 Free PMC article. No abstract available.
STAT3 Dysregulation in Mature T and NK Cell Lymphomas.
Seffens A, Herrera A, Tegla C, Buus TB, Hymes KB, Ødum N, Geskin LJ, Koralov SB. Seffens A, et al. Among authors: herrera a. Cancers (Basel). 2019 Nov 2;11(11):1711. doi: 10.3390/cancers11111711. Cancers (Basel). 2019. PMID: 31684088 Free PMC article. Review.
A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: herrera a. bioRxiv [Preprint]. 2021 Feb 19:2020.08.28.272880. doi: 10.1101/2020.08.28.272880. bioRxiv. 2021. Update in: J Virol. 2021 Feb 23;95(7):JVI.01819-20. doi: 10.1128/JVI.01819-20 PMID: 32869028 Free PMC article. Updated. Preprint.
A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, Steppan C, Devlin JC, Ivanova E, Herrera A, Schinlever A, Loose P, Ruggles K, Koralov SB, Anderson AS, Binder J, Dittmann M. de Vries M, et al. Among authors: herrera a. J Virol. 2021 Mar 10;95(7):e01819-20. doi: 10.1128/JVI.01819-20. Epub 2021 Feb 23. J Virol. 2021. PMID: 33622961 Free PMC article.
mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infection.
Ivanova EN, Shwetar J, Devlin JC, Buus TB, Gray-Gaillard S, Koide A, Cornelius A, Samanovic MI, Herrera A, Mimitou EP, Zhang C, Karmacharya T, Desvignes L, Ødum N, Smibert P, Ulrich RJ, Mulligan MJ, Koide S, Ruggles KV, Herati RS, Koralov SB. Ivanova EN, et al. Among authors: herrera a. medRxiv [Preprint]. 2023 Aug 23:2021.04.20.21255677. doi: 10.1101/2021.04.20.21255677. medRxiv. 2023. Update in: iScience. 2023 Nov 24;26(12):108572. doi: 10.1016/j.isci.2023.108572 PMID: 33907755 Free PMC article. Updated. Preprint.
SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2.
Lu Q, Liu J, Zhao S, Gomez Castro MF, Laurent-Rolle M, Dong J, Ran X, Damani-Yokota P, Tang H, Karakousi T, Son J, Kaczmarek ME, Zhang Z, Yeung ST, McCune BT, Chen RE, Tang F, Ren X, Chen X, Hsu JCC, Teplova M, Huang B, Deng H, Long Z, Mudianto T, Jin S, Lin P, Du J, Zang R, Su TT, Herrera A, Zhou M, Yan R, Cui J, Zhu J, Zhou Q, Wang T, Ma J, Koralov SB, Zhang Z, Aifantis I, Segal LN, Diamond MS, Khanna KM, Stapleford KA, Cresswell P, Liu Y, Ding S, Xie Q, Wang J. Lu Q, et al. Among authors: herrera a. Immunity. 2021 Jun 8;54(6):1304-1319.e9. doi: 10.1016/j.immuni.2021.05.006. Epub 2021 May 9. Immunity. 2021. PMID: 34048708 Free PMC article.
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, Huang SM, Bahamon C, Wu WL, Karadal-Ferrena B, Herrera A, Ivanova E, Cross M, Bossowski JP, Ding H, Hayashi M, Rajalingam S, Karakousi T, Sayin VI, Khanna KM, Wong KK, Wild R, Tsirigos A, Poirier JT, Rudin CM, Davidson SM, Koralov SB, Papagiannakopoulos T. Pillai R, et al. Among authors: herrera a. bioRxiv [Preprint]. 2023 Jun 28:2023.06.27.546750. doi: 10.1101/2023.06.27.546750. bioRxiv. 2023. Update in: Sci Adv. 2024 Mar 29;10(13):eadm9859. doi: 10.1126/sciadv.adm9859 PMID: 37425844 Free PMC article. Updated. Preprint.
1,234 results